TFEB has emerged as a therapeutic modulator in lysosomal storage diseases [90,91] and a promising target in the treatment of neurodegenerative disorders (ND), such as Alzheimer’s disease and Parkinson’s diseases [92,93]. Here, TFEB is linked to early-onset autosomal dominant Alzheimer disease.